
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn ii | New Drug Application | 2022-05-04 |
| aminosyn-pf | New Drug Application | 2022-07-21 |
| clinimix | New Drug Application | 2021-04-13 |
| clinimix e | New Drug Application | 2021-04-13 |
| clinisol | ANDA | 2018-06-01 |
| kabiven | New Drug Application | 2025-09-11 |
| novoseven | Biologic Licensing Application | 2010-08-06 |
| perikabiven | New Drug Application | 2025-09-15 |
| plenamine | ANDA | 2023-04-21 |
| premasol - sulfite-free (amino acid) | ANDA | 2022-08-04 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | — | H35.9 | — | 1 | — | — | — | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 1 | — | — | — | 1 |
| Drug common name | Histidine |
| INN | histidine |
| Description | L-histidine is the L-enantiomer of the amino acid histidine. It has a role as a nutraceutical, a micronutrient, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a human metabolite, an algal metabolite and a mouse metabolite. It is a proteinogenic amino acid, a histidine and a L-alpha-amino acid. It is a conjugate base of a L-histidinium(1+). It is a conjugate acid of a L-histidinate(1-). It is an enantiomer of a D-histidine. It is a tautomer of a L-histidine zwitterion. |
| Classification | Small molecule |
| Drug class | H2-receptor antagonists (cimetidine type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1c[nH]cn1)C(=O)O |
| PDB | — |
| CAS-ID | 71-00-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL17962 |
| ChEBI ID | 15971 |
| PubChem CID | 6274 |
| DrugBank | DB00117 |
| UNII ID | 4QD397987E (ChemIDplus, GSRS) |



